Published in
Elsevier, Lancet Haematology, 3(5), p. e109-e116, 2018
DOI: 10.1016/s2352-3026(18)30018-8
Links
Tools
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Journal article published in 2018 by
Mats Jerkeman,
Christian Winther Eskelund,
Martin Hutchings,
Riikka Räty,
Karin Fahl Wader,
Anna Laurell,
Helle Toldbod,
Lone Bredo Pedersen,
Carsten Utoft Niemann,
Christina Dahl,
Hanne Kuitunen,
Christian H. Geisler,
Kirsten Grønbæk 
,
Arne Kolstad
,
Arne Kolstad
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 